Parker AL - Search Results

1

Oncolytic Adenovirus: Strategies and Insights for Vector Design and Immuno-Oncolytic Applications.

Uusi-Kerttula H, Hulin-Curtis S, Davies J, Parker AL. Uusi-Kerttula H, et al. Among authors: parker al. Viruses. 2015 Nov 24;7(11):6009-42. doi: 10.3390/v7112923. Viruses. 2015. PMID: 26610547 Free PMC article. Review.

2

Retargeting adenovirus serotype 48 fiber knob domain by peptide incorporation.

Coughlan L, Uusi-Kerttula H, Ma J, Degg BP, Parker AL, Baker AH. Coughlan L, et al. Among authors: parker al. Hum Gene Ther. 2014 Apr;25(4):385-94. doi: 10.1089/hum.2014.016. Epub 2014 Apr 11. Hum Gene Ther. 2014. PMID: 24617540

3

Incorporation of Peptides Targeting EGFR and FGFR1 into the Adenoviral Fiber Knob Domain and Their Evaluation as Targeted Cancer Therapies.

Uusi-Kerttula H, Legut M, Davies J, Jones R, Hudson E, Hanna L, Stanton RJ, Chester JD, Parker AL. Uusi-Kerttula H, et al. Among authors: parker al. Hum Gene Ther. 2015 May;26(5):320-9. doi: 10.1089/hum.2015.015. Hum Gene Ther. 2015. PMID: 25919378 Free PMC article.

4

Pseudotyped αvβ6 integrin-targeted adenovirus vectors for ovarian cancer therapies.

Uusi-Kerttula H, Davies J, Coughlan L, Hulin-Curtis S, Jones R, Hanna L, Chester JD, Parker AL. Uusi-Kerttula H, et al. Among authors: parker al. Oncotarget. 2016 May 10;7(19):27926-37. doi: 10.18632/oncotarget.8545. Oncotarget. 2016. PMID: 27056886 Free PMC article.

5

Evaluation of CD46 re-targeted adenoviral vectors for clinical ovarian cancer intraperitoneal therapy.

Hulin-Curtis SL, Uusi-Kerttula H, Jones R, Hanna L, Chester JD, Parker AL. Hulin-Curtis SL, et al. Among authors: parker al. Cancer Gene Ther. 2016 Jul;23(7):229-34. doi: 10.1038/cgt.2016.22. Epub 2016 May 27. Cancer Gene Ther. 2016. PMID: 27229159 Free PMC article.

6

The Novel Oncolytic Adenoviral Mutant Ad5-3Δ-A20T Retargeted to αvβ6 Integrins Efficiently Eliminates Pancreatic Cancer Cells.

Man YKS, Davies JA, Coughlan L, Pantelidou C, Blázquez-Moreno A, Marshall JF, Parker AL, Halldén G. Man YKS, et al. Among authors: parker al. Mol Cancer Ther. 2018 Feb;17(2):575-587. doi: 10.1158/1535-7163.MCT-17-0671. Mol Cancer Ther. 2018. PMID: 29367266

7

Ad5_NULL-A20: A Tropism-Modified, αvβ6 Integrin-Selective Oncolytic Adenovirus for Epithelial Ovarian Cancer Therapies.

Uusi-Kerttula H, Davies JA, Thompson JM, Wongthida P, Evgin L, Shim KG, Bradshaw A, Baker AT, Rizkallah PJ, Jones R, Hanna L, Hudson E, Vile RG, Chester JD, Parker AL. Uusi-Kerttula H, et al. Among authors: parker al. Clin Cancer Res. 2018 Sep 1;24(17):4215-4224. doi: 10.1158/1078-0432.CCR-18-1089. Epub 2018 May 24. Clin Cancer Res. 2018. PMID: 29798908

8

Histone deacetylase inhibitor trichostatin A sensitises cisplatin-resistant ovarian cancer cells to oncolytic adenovirus.

Hulin-Curtis SL, Davies JA, Jones R, Hudson E, Hanna L, Chester JD, Parker AL. Hulin-Curtis SL, et al. Among authors: parker al. Oncotarget. 2018 May 29;9(41):26328-26341. doi: 10.18632/oncotarget.25242. eCollection 2018 May 29. Oncotarget. 2018. PMID: 29899862 Free PMC article.

9

Precision virotherapies: Coming soon.

Uusi-Kerttula H, Parker AL. Uusi-Kerttula H, et al. Among authors: parker al. Oncotarget. 2018 Nov 2;9(86):35605-35606. doi: 10.18632/oncotarget.26280. eCollection 2018 Nov 2. Oncotarget. 2018. PMID: 30479689 Free PMC article. No abstract available.

10

Diversity within the adenovirus fiber knob hypervariable loops influences primary receptor interactions.

Baker AT, Greenshields-Watson A, Coughlan L, Davies JA, Uusi-Kerttula H, Cole DK, Rizkallah PJ, Parker AL. Baker AT, et al. Among authors: parker al. Nat Commun. 2019 Feb 14;10(1):741. doi: 10.1038/s41467-019-08599-y. Nat Commun. 2019. PMID: 30765704 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

147 results

Search Page